Thomas J W, Plenderleith I H, Landi S, Basco V E, Clements D V
Can Med Assoc J. 1983 Sep 1;129(5):439-42.
Following complete remission of non-Hodgkin's lymphoma by chemotherapy, irradiation or both, 44 patients were studied to assess the value of bacille Calmette-Guérin (BCG) as maintenance therapy. Patients with stage LI, EI or EII disease were allocated at random to receive BCG or no further maintenance therapy, and those with stage LII, LIII, EIII or IV disease received BCG therapy or orally administered cyclophosphamide. BCG had no effect on the duration of remission or the overall survival from the time of randomization. However, after the first recurrence there was a significant improvement in survival in the patients who had received BCG maintenance therapy.
在通过化疗、放疗或两者结合使非霍奇金淋巴瘤完全缓解后，对44例患者进行了研究，以评估卡介苗（BCG）作为维持治疗的价值。I期、IIE期或IIE期疾病的患者被随机分配接受卡介苗治疗或不再接受进一步的维持治疗，而II期、III期、IIIE期或IV期疾病的患者接受卡介苗治疗或口服环磷酰胺。从随机分组时起，卡介苗对缓解期持续时间或总生存率没有影响。然而，在首次复发后，接受卡介苗维持治疗的患者生存率有显著提高。
